Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn
Read the original post:
Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn
Promising Results for Stem Cell Treatment of Degenerative …
By Pat Anson, PNN Editor
An Australian regenerative medicine company has released positive results from a Phase III randomized trial showing that a single injection of its proprietary stem cell product can provide long-term relief for people with chronic lower back pain caused by degenerative disc disease.
Mesoblast Limited said the results are so promising it plans to meet with the U.S. Food and Drug Administration to discuss ways to accelerate approval of the drug as a treatment that reduces the use of opioid pain medication.
The companys stem cell product -- remestemcel-L -- has been under development for several years. It uses mesenchymal precursor cells taken from the bone marrow of healthy donors to reduce inflammation by inhibiting the production of pro-inflammatory cytokines by white blood cells.
Sixty percent of the patients in the clinical trial who were injected with remestemcel-L reported minimal or no pain after 12 months. After 24 months, 54 percent reported little or no pain, with the greatest pain reduction in patients in the early stages of degenerative disc disease. Many patients also significantly reduced their use of opioids during the study period.
The durable pain reduction for at least two years from a single administration indicates that rexlemestrocel-L has the potential to change the treatment paradigm for chronic low back pain due to inflammatory disc disease, a condition that affects as many as seven million patients across the United States and Europe, and to prevent or reduce opioid use and dependence, Dr. Silviu Itescu, CEO of Mesoblast, said in a statement.
Over 400 patients were enrolled in the Phase III trial, which was conducted at 48 sites around the world, mostly in the United States. Although Mesoblast told physicians and patients not to change any medications during the trial, after 24 months there was a 40% reduction in opioid use in patients injected with rexlemestrocel-L. Those who were given a placebo saline injection increased their daily opioid consumption.
In a previous study of patients with chronic lower back pain who did not respond to conventional treatment, a single injection of remestemcel-L also reduced pain for at least two years.
The FDA has prioritized the development of new pain treatments that reduce the use of opioids. Although the agency has taken a dim view of some stem cell therapies as unproven and potentially dangerous, Mesoblast believes the FDA will be more open-minded about its rexlemestrocel-L treatment. Last year the agency approved an investigational new drug application for rexlemestrocel-L as a therapy for COVID-19.
We now have two studies that show significant pain reduction and were fully prepared to have a discussion with FDA on a path forward, said Mesoblast Chief Medical Officer Dr. Fred Grossman. Were going to get into discussions to see if theres an accelerated path. Or, if we do need to do another study, we now have a very defined patient population where we see significant pain reduction.
Read more:
Promising Results for Stem Cell Treatment of Degenerative ...
Stem Cell Therapy for Heart Disease – Cleveland Clinic
Overview Stem Cell Therapy: Helping the Body Heal Itself
Stem cells are natures own transformers. When the body is injured, stem cells travel the scene of the accident. Some come from the bone marrow, a modest number of others, from the heart itself. Additionally, theyre not all the same. There, they may help heal damaged tissue. They do this by secreting local hormones to rescue damaged heart cells and occasionally turning into heart muscle cells themselves. Stem cells do a fairly good job. But they could do better for some reason, the heart stops signaling for heart cells after only a week or so after the damage has occurred, leaving the repair job mostly undone. The partially repaired tissue becomes a burden to the heart, forcing it to work harder and less efficiently, leading to heart failure.
Initial research used a patients own stem cells, derived from the bone marrow, mainly because they were readily available and had worked in animal studies. Careful study revealed only a very modest benefit, so researchers have moved on to evaluate more promising approaches, including:
No matter what you may read, stem cell therapy for damaged hearts has yet to be proven fully safe and beneficial. It is important to know that many patients are not receiving the most current and optimal therapies available for their heart failure. If you have heart failure, and wondering about treatment options, an evaluation or a second opinion at a Center of Excellence can be worthwhile.
Randomized clinical trials evaluating these different approaches typically allow enrollment of only a few patients from each hospital, and hence what may be available at the Cleveland Clinic varies from time to time.
Cleveland Clinic is a large referral center for advanced heart disease and heart failure we offer a wide range of therapies including medications, devices and surgery. Patients will be evaluated for the treatments that best address their condition. Whether patients meet the criteria for stem cell therapy or not, they will be offered the most advanced array of treatment options.
Allogenic: from one person to another (for example: organ transplant)
Autogenic: use of one's own tissue
Myoblasts: immature muscle cells, may be able to change into functioning heart muscle cells
Stem Cells: cells that have the ability to reproduce, generate new cells, and send signals to promote healing
Transgenic: Use of tissue from another species. (for example: some heart valves from porcine or bovine tissue)
Last reviewed by a Cleveland Clinic medical professional on 01/03/2019.
Read this article:
Stem Cell Therapy for Heart Disease - Cleveland Clinic
Stem Cell Therapy for Stroke Recovery | University of …
This procedure uses a combination of X-rays and computer technology to produce cross-sectional images of the body both horizontally and vertically, to detect abnormalities and help identify the location or type of stroke.
MRI uses magnetic fields to detect small changes in brain tissue that help to locate and diagnose stroke.
This nuclear brain scan uses radioactive compounds injected into a vein in the arm, and a machine (similar to a Geiger counter) to create a map showing their uptake into different parts of the head, often detecting areas of decreased blood flow and tissue damage.
This special type of CT scan can look at specific blood vessels within the body.
Using MRI technology, this procedure evaluates blood flow through arteries in a noninvasive way.
This variation of MRI is used to determine the specific location of the brain where a certain function, such as speech or memory, occurs.
This procedure records the brain's continuous, electrical activity by means of electrodes attached to the scalp.
This test records the brain's electrical response to visual, auditory, and sensory stimuli.
A small microphone is placed over the carotid artery on the neck to record sounds created by blood flow as it passes through a partially blocked artery.
A special transducer is used to direct sound waves into a blood vessel to evaluate the sound of blood moving though the vessel, looking for faintness or absence of sound.
This test measures pressure on the eyes, or detects pulses in the eyes.
This test measures the amount of oxygen in the blood supply that reaches different areas of the brain.
The test involves inserting a small, thin tube (catheter) into an artery in the leg and passing it up to the blood vessels in the brain. A contrast dye is injected through the catheter and X-ray images are taken.
Link:
Stem Cell Therapy for Stroke Recovery | University of ...
Stem Cell Treatment: Future of Modern Medicine | Science Times
(Photo : https://www.pexels.com/photo/clinic-doctor-health-hospital-4154/)
What are stem cells?
Stem cells, also known as "master cells," are body cells from which "daughter cells" are generated from. The daughter cells are processed to become new cells or specialized cells that may function as heart cells, bone cells, blood cells, brain cells and other forms of cells needed for patients to recuperate from an injury or illness.
Stem cell treatment is a state-of-the-art regenerative medicine that aims to provide relief, repair, and regrowth to damaged or injured tissues. This type of treatment is minimally invasive, non-opioid, and non-surgical. Thus, it reduces the risks of complications and adverse reactions.
How does stem cell treatment work?
Stem cells are taken directly from one part of the patient's body and are processed in a centrifuge machine that produces concentrated stem cell substances. The concentrated substance is then injected into the patient's affected body part.
Stem cells are concentrated to specifically treat the injured or affected part of the human body. It works according to certain medical specifications. Some stem cells are processed to have a "specialized" function. These are cases when stem cells are used to specifically repair damaged body organs including the brain, heart, blood, muscle and soft and hard tissues of the body.
Stem cell treatment has the power to alter conventional medical procedures to more innovative and state-of-the-art practice. This treatment uses the regenerative power of stem cells to relieve patients from pain, injury, trauma, and disease.
The use of stem cells is a relatively new technology. It has shown promising potentials of providing a wide variety of treatment for diseases by generating specific stem cell concentrate. Thus, many medical authorities consider stem cells as the "future of modern medicine."
Stem cells contain natural growth factors that accelerate the body's healing response. It can also help manage pain caused by injuries sustained without the need for pain-killing medications.
The use of stem cells in regenerative medicine provides many advantages in pain management and other medical procedures. The benefits of stem cell treatments include effective pain reduction, minimal post-procedural recovery, increased body functionality, flexibility and mobility, prevention of nerve damage, and potential injury reversal.
Other benefits include reducing the need for long-term medication, lowering the risks of surgery and complications, non-administration of anesthesia, and improving collagen production in the body. Stem cell procedures also lower the risks of spreading diseases from one person to another since the stem cell is originally taken from the patient's own body.
Stem cell is taking the world of medicine to the next level! Indeed, it is the future of modern medicine!
See the article here:
Stem Cell Treatment: Future of Modern Medicine | Science Times
Researchers may have found a miracle cure for baldness – BGR
Many people have been trying to cure a medical condition that affects millions of people worldwide, with men predominantly affected by it. Baldness can be triggered by specific drug therapies, like cancer treatment, and some COVID-19 survivors have discovered that hair loss is an unusual symptom. But baldness occurs in many others without a specific trigger. By the age of 35, two-thirds of American men will experience some degree of hair loss, according to the American Hair Loss Association. By the age of 50, up to 85% of men will experience significantly thinning hair.
Baldness does not impact ones health, but it can extract an emotional toll on those who are impacted by it. There are various therapies for baldness, but theres no cure that can reverse the process. Now, however, a team in Japan might have found a solution to restore hair growth with the help of stem cells.
Today's Top Deal Price: Available from Amazon, BGR may receive a commission Buy NowCoupon Code: Available from Amazon BGR may receive a commission
The researchers used stem cells to create hair follicles that can regrow hair after it falls out. Thats how hair growth should function. Hair loss is natural, but every strand of hair should be replaced by a new one that regrows in its place. The RIKEN Center for Biosystems Dynamics Research scientists published a paper in Nature Scientific Reports (via Futurism) detailing their progress with stem cells on mammals.
They took fur and whisker cells from mice and then cultured them in the lab together with other ingredients. They used 220 combinations, finding that one type of collagen paired with five factors (NFFSE medium) would lead to the highest rate of stem cell amplification in the shortest period of time. The RIKEN team explained that a successful hair-regeneration treatment that could cure baldness must produce hair that recycles. That means the hair can regrow after falling out naturally.
These researchers combined bioengineered hair follicle stem cells with the NFFSE medium, as well as with the medium missing one of the ingredients. They observed the regenerated hair for three weeks and discovered that the NFFSE medium allowed the hair follicles to go through at least three cycles of normal hair production. The other medium wasnt nearly as efficient, with 79% of follicles producing only one hair cycle.
The researchers also found that a specific marker on the surface of cells cultured in the NFFSE medium favored hair cycling. We found almost 80% of follicles reached three hair cycles when Itg5 was also bioengineered into the hair follicle germ, author Makoto Takeo said in a statement. In contrast, only 13% reached three cycles when it was not present.
Our culture system establishes a method for cyclical regeneration of hair follicles from hair follicle stem cells and will help make hair follicle regeneration therapy a reality in the near future, Takashi Tsuji, the lead author of the study, said.
Before this baldness cure becomes commercially available, it has to pass clinical trials. So far, the RIKEN researchers have demonstrated stem cell therapy in preclinical lab tests. Tsuji said that the institute is looking for outside collaborators to help develop clinical applications for the new hair growth technology.
The full study is available at this link.
Today's Top Deal Honeywell cloth face masks are in stock on Amazon at the lowest price ever! List Price:$29.99 Price:$22.25 You Save:$7.74 (26%) Available from Amazon, BGR may receive a commission Buy Now Available from Amazon BGR may receive a commission
Chris Smith started writing about gadgets as a hobby, and before he knew it he was sharing his views on tech stuff with readers around the world. Whenever he's not writing about gadgets he miserably fails to stay away from them, although he desperately tries. But that's not necessarily a bad thing.
Read the original post:
Researchers may have found a miracle cure for baldness - BGR
Types of leukemia: Prevalence, treatment options, and prognosis – Medical News Today
Leukemia is a type of cancer that affects the blood and bone marrow, where blood cells are formed. All types of leukemia cause rapid, uncontrolled growth of abnormal bone marrow and blood cells.
The main differences between the types include how fast the disease progresses and the types of cells it affects.
There are four main types of leukemia, which we describe in detail below:
Lymphocytic leukemia affects the lymphocytes, a type of white blood cell. Myeloid leukemia can affect the white blood cells, red blood cells, and platelets.
According to the National Cancer Institute, roughly 1.5% of people in the United States will receive a leukemia diagnosis at some point.
In this article, explore the four main types, their symptoms, the treatment options available, and the outlook.
The full name of this type of cancer is acute lymphocytic leukemia, and acute means that it grows quickly. Lymphocytic means that it forms in underdeveloped white blood cells called lymphocytes.
The disease starts in the bone marrow, which produces stem cells that develop into red and white blood cells and platelets.
In a healthy person, the bone marrow does not release these cells until they are fully developed. In someone with ALL, the bone marrow releases large quantities of underdeveloped white blood cells.
There are several subtypes of ALL, and the subtype may influence the best course of treatment and the prognosis.
One subtype is B-cell ALL. This begins in the B lymphocytes, and it is the most common form of ALL in children.
Another subtype is T-cell ALL. It can cause the thymus, a small organ at the front of the windpipe, to become enlarged, which can lead to breathing difficulties.
Overall, because ALL progresses quickly, swift medical intervention is key.
As research from 2020 acknowledges, healthcare providers still do not know what causes ALL. It may occur due to genetic factors or exposure to:
Although genetic factors may play a role, ALL is not a familial disease.
Learn more about ALL here.
ALL is the most common form of leukemia in children.
The risk of developing it is highest in children under 5 years old. The prevalence slowly rises again in adults over 50.
ALL symptoms can be nonspecific difficult to distinguish from those of other illnesses.
They may include:
In a person with AML, the bone marrow makes abnormal versions of platelets, red blood cells, and white blood cells called myeloblasts.
The full name of this disease is acute myeloid leukemia, and acute refers to the fact that it is fast-growing.
It forms in one of the following types of bone marrow cell:
Doctors classify AML by subtype, depending on:
AML can be difficult to treat and requires prompt medical attention.
Learn more about AML here.
The most common risk factor is myelodysplastic syndrome, a form of blood cancer that keeps the body from producing enough healthy blood cells.
Other factors that increase the risk of developing AML include:
Most people who develop AML are over 45. It is one of the most common types of leukemia in adults, though it is still rare, compared with other cancers.
It is also the second most common form of leukemia in children.
Symptoms of AML can vary and may include:
CLL is the most common form of leukemia among adults in the U.S. and other Western countries.
There are two types. One progresses slowly, and it causes the body to have high levels of characteristic lymphocytes, but only slightly low levels of healthy red blood cells, platelets, and neutrophils.
The other type progresses more quickly and causes a significant reduction in levels of all healthy blood cells.
In someone with CLL, the lymphocytes often look fully formed but are less able to fight infection than healthy white blood cells. The lymphocytes tend to build up very slowly, so a person might have CLL for a long time before experiencing symptoms.
Learn more about CLL here.
Genetic factors are the most likely cause. Others might include:
CLL is rare in children. It typically develops in adults aged 70 or over. However, it can affect people as young as 30.
CLL typically causes no early symptoms. When symptoms are present, they may include:
Also, 5090% of people with CLL have swollen lymph nodes.
CML is a slow-growing type of leukemia that develops in the bone marrow.
The full name of CML is chronic myeloid leukemia. As the American Cancer Society explain, a genetic change takes place in the early forms of the myeloid cells, and this eventually results in CML cells.
These leukemia cells then grow, divide, and enter the blood.
CML occurs due to a rearrangement of genetic material between the chromosomes 9 and 22.
This rearrangement fuses a part of the ABL1 gene from chromosome 9 with the BCR gene from chromosome 22, called the Philadelphia chromosome. The result of this fusion is called BCR-ABL1.
BCR-ABL1 produces a protein that promotes cell division and stops apoptosis, the process of cell death, which typically removes unneeded or damaged cells.
The cells keep dividing and do not self-destruct, resulting in an overproduction of abnormal cells and a lack of healthy blood cells.
This occurs during the persons lifetime and is not inherited.
CML typically affects adults. People aged 65 and older make up almost half of those who receive a CML diagnosis.
The symptoms of CML are unclear, but they may include:
The symptoms may vary, depending on the type of leukemia. Overall, a person should get in touch with a doctor if they experience:
Learn more about the symptoms of leukemia here.
Treatment for ALL typically involves three basic phases: induction, consolidation, and maintenance. We describe these in detail below.
Treatment for AML involves the first two phases. The induction phase may include treatment with the chemotherapy drugs cytarabine (Cytosar-U) and daunorubicin (Cerubidine) or idarubicin (Idamycin). The doctor may also recommend targeted drugs.
The goal of this phase is to kill the leukemia cells, causing the cancer to go into remission, using chemotherapy.
The doctor may recommend:
People having chemotherapy may need to see their doctors frequently and spend time in the hospital, due to the risk of serious infections and complications.
This phase of the treatment lasts for about 1 month.
Even if the treatment so far has led to remission, cancer cells may be hiding in the body, so more treatment is necessary.
The consolidation phase may involve taking high doses of chemotherapy. A doctor may also recommend targeted drugs or stem cell transplants.
This phase, consisting of ongoing chemotherapy treatments, usually lasts for 2 years.
Since CLL tends to progress slowly, and its treatment can have unpleasant side effects, some people with this condition go through a phase of watchful waiting before starting the treatment.
For a person with CML, the focus is often on providing the right treatment for the phase of the illness. To do this, a doctor considers how quickly the leukemia cells are building up and the extent of the symptoms. Stem cell transplants can be effective, but further treatment is necessary.
Overall, the initial treatment tends to include monoclonal antibodies, targeted drugs, and chemotherapy.
If the only concern is an enlarged spleen or swollen lymph nodes, the person may receive radiation or surgery.
If there are high numbers of CLL cells, the doctor may suggest leukapheresis, a treatment that lowers the persons blood count. This is only effective for a short time, but it allows the chemotherapy to start working.
For people with high-risk disease, doctors may recommend stem cell transplants.
A persons prognosis depends on the type of leukemia.
Learn more about survival rates for people with leukemia here.
About 8090% of adults with ALL experience complete remission for a while during treatment. And with treatment, most children recover from the disease.
Relapses are common in adults, so the overall cure rate is 40%. However, factors specific to each person play a role.
The older a person is when they receive an AML diagnosis, the more difficult it is to treat.
More than 25% of adults who achieve remission live for 3 years or more after treatment for AML.
A person may live for a long time with CLL.
Treatments can help keep the symptoms under control and prevent the disease from spreading. However, there is no cure.
Stem cell transplants can cure CML. However, this treatment is very invasive and is not suitable for most people with CML.
The United Kingdoms National Health Service estimate that 70% of males and 75% of females live for at least 5 years after receiving a CML diagnosis.
The earlier a person receives the diagnosis, the better their outlook.
Leukemia is a type of cancer that affects the blood and bone marrow. It can affect people of all ages.
There are four main types of leukemia. They differ based on how quickly they progress and the types of cells they affect.
Treatments for all types of leukemia continue to improve, helping people live longer and more fully with this condition.
Excerpt from:
Types of leukemia: Prevalence, treatment options, and prognosis - Medical News Today
Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease -…
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced the launch of a Phase 1/2 clinical trial to evaluate JSP191, Jaspers first-in-class anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning regimen prior to allogeneic transplant for sickle cell disease (SCD). Jasper Therapeutics and the National Heart, Lung, and Blood Institute (NHLBI) have entered into a clinical trial agreement in which NHLBI will serve as the Investigational New Drug (IND) sponsor for this study.
SCD is a lifelong inherited blood disorder that affects hemoglobin, a protein in red blood cells that delivers oxygen to tissues and organs throughout the body. Approximately 300,000 infants are born with SCD annually worldwide, and the number of cases is expected to significantly increase. Currently, hematopoietic stem cell transplantation (HSCT) is the only cure available for SCD.
"This clinical trial agreement with the NHLBI expands the development of JSP191 for transplant conditioning and could bring curative transplants to more patients in need," said Kevin N. Heller, M.D., Executive Vice President, Research and Development, of Jasper Therapeutics. "We look forward to collaborating with the NHLBI and learning more about the potential for JSP191 in patients living with sickle cell disease."
About JSP191
JSP191 (formerly AMG 191) is a first-in-class humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from the bone marrow. JSP191 binds to human CD117, a receptor for stem cell factor (SCF) that is expressed on the surface of hematopoietic stem and progenitor cells. The interaction of SCF and CD117 is required for stem cells to survive. JSP191 blocks SCF from binding to CD117 and disrupts critical survival signals in stem cells leading to cell death. This creates space in the bone marrow for engraftment of donor or gene-corrected transplanted stem cells.
Preclinical studies have shown that JSP191, as a single agent, safely depletes normal and diseased hematopoietic stem cells, including in animal models of severe combined immunodeficiency (SCID), myelodysplastic syndromes (MDS), and sickle cell disease (SCD). Treatment with JSP191 creates the space needed for transplanted normal donor or gene-corrected hematopoietic stem cells to successfully engraft in the host bone marrow. To date, JSP191 has been evaluated in more than 90 healthy volunteers and patients.
JSP191 is currently being evaluated in two separate Jasper Therapeutics-sponsored clinical studies in hematopoietic cell transplant. The first clinical study is evaluating JSP191 as a sole conditioning agent in a Phase 1/2 dose-escalation and expansion trial to achieve donor stem cell engraftment in patients undergoing hematopoietic cell transplant for SCID. Blood stem cell transplantation offers the only potentially curative therapy for SCID. JSP191 is also being evaluated in combination with another conditioning regimen in a Phase 1 study in patients with MDS or acute myeloid leukemia (AML) who are receiving hematopoietic cell transplant. For more information about the design of these clinical trials, visit http://www.clinicaltrials.gov (NCT02963064 and NCT04429191).
Additional studies are planned to advance JSP191 as a conditioning agent for patients with other rare and ultra-rare monogenic disorders and autoimmune diseases.
About Jasper Therapeutics
Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The companys lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplant. This first-in-class conditioning antibody is designed to enable safer and more effective curative hematopoietic cell transplants and gene therapies. For more information, please visit us at jaspertherapeutics.com.
Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 – The Courier
The global stem cell therapy market is expected to witness a CAGR of 10.6% during the forecast period 2019-2024, and is also anticipated to reach USD 214.5 million by 2024. Growing awareness related to the therapeutic potency of stem cells, development of infrastructure related to stem cell banking and processing, development of advanced genome-based cell analysis techniques, and increasing private-public investment for the development of stem cell therapies are driving the growth of the stem cell therapy market.
Get a free copy of sample report: https://www.vynzresearch.com/healthcare/stem-cell-therapy-market/request-sample
Supportive regulations to drive the growth of the stem cell therapy market
Supporting regulations across developing countries, increasing prevalence of chronic diseases, technological advancement in healthcare, cellular therapies are the major advancements in transforming healthcare and identification of new stem cell lines are also fueling the growth of the stem cell therapy market.
Diseases such as osteoarthritis, multiple sclerosis, heart failure, hearing loss and cerebral palsy are some of the diseases that could be treated using stem cell therapies. For instance, according to the WHO by 2050, it is estimated 900 million people will have disabling hearing loss. Moreover, 60 percent of childhood hearing loss is due to preventable causes.
Allogenic stem cell therapy market to hold the larger share in the market
There are two types of stem cell therapy, allogeneic and autologous. Of both, allogenic segment account for the larger share and is also predicted to grow at the faster rate in the coming years in the market due to its extensive therapeutic applications, increasing commercialization of allogeneic products, easy production scale-up process, and growing number of clinical trials related to allogeneic therapies.
The stem cell therapy market has been segmented by therapeutic application into gastrointestinal diseases, musculoskeletal disorders, surgeries, cardiovascular diseases, and wound and injuries. Musculoskeletal disorders category contributed the largest revenue in the market due to increasing prevalence of musculoskeletal disorders and bone & joint diseases, increasing availability of stem cell-based products for the treatment of musculoskeletal disorders, and growing patient preference for effective & early treatment strategies.
Do you have any specific research requirement? Ask for customization: https://www.vynzresearch.com/healthcare/stem-cell-therapy-market/customize-report
The global stem cell therapy market has also been segmented by cell source into adipose tissue-derived mesenchymal stem cell, cord blood cells and bone marrow-derived mesenchymal stem cells. Of all the categories, the bone marrow-derived mesenchymal stem cells are increasingly being used for therapeutic applications.
North America offers huge opportunities for stem cell therapy industry players
The North American stem cell therapy market will remain the largest during the forecast period. The region is further predicted to observe the fastest growth during the forecast period in the global market owing to technological upgradation and large capital invested in the research and development activities. Moreover, increasing number of clinical trials to evaluate therapeutic potential of products, increasing prevalence of chronic diseases, the growing patient base for target diseases, growing public awareness related to the therapeutic potency of therapy, and increasing public-private funding & research grants for developing safe and effective stem cell therapy products are also supporting the growth of the North American stem cell therapy market.
Investing in research and development is the key strategy adopted by the market players
Major players in the industry are investing in the development of innovative and new products, which is strengthening their position in the stem cell therapy market. In February 2018, MEDIPOST announced that FDA has approved its stem cell-based Alzheimers disease drug, NEUROSTEM for clinical trials. Similarly, in March 2017, Osiris Therapeutics launched Prestige Lyotechnology, a method for storage of living cells and tissues.
Some of the key players operating in the stem cell therapy industry are Osiris Therapeutics, Inc., RTI Surgical, Inc., MEDIPOST Co., Ltd., Nuvasive, Inc., Pharmicell Co., Ltd., Holostem Terapie Avanzate Srl, JCR Pharmaceuticals Co., Ltd., Anterogen Co., Ltd., and Allosource.
More from VynZ Research
Global Stem Cell Banking Market Analysis and Forecast to 2024
The global stem cell banking market is growing at a CAGR of 9.1% during the forecast period reaching USD 10.5 billion by 2024, due to the development of novel technologies of storage, preservation and processing. Stem cell banking is the method of accumulating cord blood, extorting and cryogenically freezing its stem cells for forthcoming use. Cord blood stem cells are used for treating blood diseases such as sickle cell disease, leukemia, and thalassemia. The global stem cell banking market is growing at a significant rate due to the development of novel technologies of storage, preservation and processing. The market has witnessed a high demand for placenta stem cells over the last few years, due to the increasing public awareness regarding the therapeutic prospective of stem cells.
Explore more at: https://www.vynzresearch.com/healthcare/stem-cell-banking-market/request-sample
Global Protein Expression Market Analysis and Forecast to 2024
The global protein expression market was evaluated at USD 1,873.1 million in 2018. The protocol for expression of proteins makes use of expression vectors, competent cells, reagents, instrument, and services. The reagents are the estimated to hold the largest share due to large volume used in the bio-experiments. The significant growth in the protein expression industry is primarily due to the increasing funds from government and non-government organization for protein research, the soaring prevalence of chronic diseases, rising life science industry.
Explore more at: https://www.vynzresearch.com/healthcare/protein-expression-market/request-sample
U.S. Protein Expression Market Analysis and Forecast to 2024
The U.S. protein expression market is expected to grow at a CAGR of 11.6% during the forecast period with its market size predicted to reach USD 1.2 billion by 2024. The U.S. protein expression market is primarily driven by the factors such as the increasing prevalence of chronic diseases, increasing investment for recombinant protein expression, advancement in technology for expression systems, increasing geriatric population, and robust growth of the life sciences industry in the country. Prokaryotic expression systems and mammalian cell expression systems are the major contributors to the protein expression industry in the region.
Explore more at: https://www.vynzresearch.com/healthcare/us-protein-expression-market/request-sample
Contact Us:
VynZ Research
Call: +91-996-028-8381
Toll Free (U.S. and Canada): +1-888-253-3960
Email: enquiry@vynzresearch.com
Connect with Us: LinkedIn | Facebook | Twitter
Read more:
Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 - The Courier
Keep it Flowing: Combating COVID-19 Blood Shortages in Cancer Treatment – Curetoday.com
When Marie Fuesel was treated for leukemia eight years ago, she needed donated blood products more than 100 times.
Theyd give me my chemotherapy, Id stay in the hospital for a week, then Id go home, get really sick and have to come back in for blood and platelets, says Fuesel, 53, a retired insurance agent who lives in suburban Chicago. I spent over 100 days in the hospital over eight months. The disease and treatments (affect the bone marrow and production of red and white blood cells and platelets), so many transfusions were required to achieve remission.
After eight months of chemotherapy, followed by a year on the targeted drug Sprycel (dasatinib) as part of a clinical trial, Fuesel went into remission. She no longer needs transfusions, but she still appreciates the need for blood donors. I wouldnt be alive if the blood wasnt available when it was needed, she says.
Back then, blood shortages werent common, but they are now. The stay-at-home orders at the beginning of the COVID-19 pandemic forced the cancellation of numerous blood drives, and safety concerns arising from its spread have prompted some frequent donors to stay away from donation centers.
Thats been a source of worry for oncologists. Patients with cancer use nearly one-quarter of the nations blood supply, according to the American Red Cross, and donated blood is a vital resource in the treatment of hematologic cancers. Patients who receive stem cell transplants often need transfusions of oxygen-carrying red blood cells, infection-fighting white blood cells and platelets to control bleeding. Blood transfusions are common in the supportive care of patients undergoing chemotherapy that suppresses production of all the blood cells that results in anemia, because they relieve symptoms that ensue, such as fatigue and shortness of breath.
Between March and June 2020, 37,000 blood drives were canceled, according to the American Red Cross. The impact of the blood shortage varied across the nation but has hit some cities particularly hard. The New York Blood Center, for example, which supplies New York City
hospitals, reported in December 2020 that it had just three days of supply on hand, down from the five- to seven-day supply it normally has.
Ongoing shortages are forcing cancer centers to change some of their procedures for using donated blood. We all recognize that we are in the midst of a public health crisis and that we all have to do our part, says Dr. Mikkael Sekeres, chief of hematology at the University of Miami Miller School of Medicine and a physician liaison in hematology at Sylvester Comprehensive Cancer Center.
In response to COVID-related blood shortages, several cancer centers adjusted their policies for transfusing blood. Moffitt Cancer Center in Tampa, Florida, for example, developed a blood shortage action plan, according to Dr. Kaaron Benson, director of the blood bank at Moffitt. It basically meant dropping some of the thresholds we would normally use for transfusion, Benson says.
Moffitt has not needed to implement the plan yet, but if it does, Benson says, the change would most likely have the biggest effect on patients with leukemia and lymphoma who are given platelets as a preventive strategy. Provided theyre not bleeding or engaging in activities that increase the risk of bleeding, studies have shown you can allow the platelet threshold to drop from our standard of 10,000 per microliter to 5,000, she says.
The technique was first suggested in a 1991 journal article and has since been widely accepted as an appropriate change to make during blood shortages, Benson says.
In recent years, many oncologists have set lower thresholds for red blood cell transfusions another change that has eased the strain on blood supply. They used to routinely order transfusions for patients with hemoglobin levels below 10 grams per deciliter. That number dropped to between 7 and 8 grams per deciliter after a series of studies showed that infusing red blood cells at the higher threshold did not improve treatment outcomes.
During the pandemic, Moffitt and other cancer centers are also delaying some stem cell transplants and elective surgeries, so that blood used during those procedures can be kept on hand for patients who urgently need it, such as trauma patients or those needing emergent surgery. But those decisions are made on a case-by-case basis, so patients should maintain a frequent dialogue with their oncologists to determine the best plan for managing their symptoms during the pandemic.
Patients with multiple myeloma, for example, can benefit from stem cell transplants, but its usually not urgent, says Dr. Stephanie Lee, a hematologist and professor at the Fred Hutchinson Cancer Research Center in Seattle. We have very good treatments for multiple myeloma, so we can continue to give patients chemotherapy for weeks or months, Lee says.
However, she explains, patients with leukemia who need stem cell transplants may be advised to undergo the procedure as quickly as possible, even during the pandemic, because delaying it could cause the cancer to grow and become resistant to treatment.
And some patients with cancer who are simultaneously fighting other diseases should receive all the blood and platelet transfusions they need to manage their cancer, as well as to address any risks posed by chronic conditions. If you have heart disease, and your hemoglobin drops even further, youre more likely to get angina or suffer a heart attack, Sekeres says. So, for those people with serious comorbidities, we are more aggressive in transfusing blood products.
Growing the Donor Pool
Stephenie Perry, who works as the business operations coordinator for the American Red Cross of Northwest Georgia, knows firsthand the value of donated blood. Perry is a survivor of Hodgkin lymphoma who needed several transfusions during her treatment, which consisted of a round of chemotherapy and two stem cell transplants.
Perry, 31, has been in remission since February 2018, but sometimes her red blood cell count still runs low and she needs another blood transfusion. I feel sluggish, and when I stand up, I get really dizzy, says Perry, who lives in Rome, Georgia. When I get a transfusion, its like someone has just given me a shot of energy.
How can patients adapt when blood shortages mandate less frequent transfusions? Lifestyle changes can make a big difference, Sekeres says. If a patient is becoming progressively anemic, and its someone who usually goes for a 2-mile walk every day, maybe theyll reduce it to 1 mile or cut (exercise) altogether, he says.
Some patients may be eligible for iron infusions, which can relieve symptoms of fatigue and lengthen the period between infusions, says Abbey Fueger, clinical trial nurse navigator for the Leukemia & Lymphoma Society.
In addition, there are other small changes that can lessen the risk of anemia and improve symptoms. Some physicians are trying to limit blood draws for patients and recommending nutritional supplements that might help them feel better and lengthen the time between infusions, she says.
Meanwhile, an effort is underway to expand the pool of potential blood donors. In April, the Food and Drug Administration (FDA) addressed blood shortages brought on by COVID-19 by easing up on some of its restrictions on who can donate. For example, people who are at risk of contracting HIV, and those who have a recent tattoo or piercing or possible exposure to an infected individual no longer have to wait one year to give blood. The new waiting period is three months.
The FDA also dropped the waiting period for donors who have traveled to malaria-endemic countries from one year to three months. And it no longer recommends that blood centers turn away donors who lived in certain European countries during the era when Creutzfeldt-Jakob disease, a rare and fatal degenerative brain disorder, was thought to be spreading.
The hospital community is rallying around the cause, holding blood drives of their own and encouraging family members of patients to donate blood.
During the first few months of the pandemic, Fuesel helped put together five small blood drives in her town of Orland Park, Illinois. They were so successful the American Red Cross and a local news broadcaster asked her to help run the seventh annual Great Chicago Blood Drive. So, she did, and on Jan. 13, that event collected 330 units of blood at the Orland Park location and more than 2,000 units at other drives around the city.
For donors who might be nervous about giving blood during a pandemic, Fuesel has a message: Its safe and important. All the beds are spaced apart, and there are different stations when you walk in for getting your temperature checked and using hand sanitizer, Fuesel says. I know these are hard times, but it doesnt cost anything to give your blood. Its a way to help.
The rest is here:
Keep it Flowing: Combating COVID-19 Blood Shortages in Cancer Treatment - Curetoday.com